PDF herunterladen
Aktuelle Kardiologie 2012; 1(3): 185-191
DOI: 10.1055/s-0032-1315039
Übersichtsarbeit
Georg Thieme Verlag KG Stuttgart · New York

Antiarrhythmische Therapie bei Vorhofflimmern

Antiarrhythmic Drug Therapy for Atrial Fibrillation
Agnes Fink
1   Fachbereich Kardiologie, Deutsche Klinik für Diagnostik, Wiesbaden
,
Joachim R. Ehrlich
1   Fachbereich Kardiologie, Deutsche Klinik für Diagnostik, Wiesbaden
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
15. August 2012 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Vorhofflimmern tritt bei einer Vielzahl kardiologischer Grunderkrankungen auf und führt in vielen Fällen zu beträchtlicher Symptomatik. Die Rhythmusstörung sollte zunächst (nach Einleitung einer oralen Antikoagulation entsprechend Risikoscores) mit einer Medikation zur Kontrolle der Kammerfrequenz behandelt werden. Führt dies nicht zu der erwünschten Besserung der Beschwerden, ist eine Therapie zu Wiederherstellung und Erhalt des Sinusrhythmus indiziert. Kommt es hierunter zu symptomatischen Rezidiven sollte die Indikation zu einer Ablationstherapie geprüft werden.

Abstract

Atrial fibrillation occurs in the context of several cardiac disease entities and may lead to significant symptoms. In general, the arrhythmia should initially (after initiation of an oral anticoagulation according to risk stratification schemes) be treated in an attempt to control ventricular rate. If this does not lead to sufficient relief of symptoms, further medical therapy that aims at restoration and maintenance of sinus rhythm should be applied. If there are still symptomatic relapses with such medication an ablation therapy should be considered.

Schlüsselwörter

Vorhofflimmern - Antiarrhythmika - Rezidivprophylaxe - medikamentöse Kardioversion

Key words

atrial fibrillation - antiarrhythmic drugs - relapse prevention - pharmacological cardioversion
 

  • Literatur

  • 1 Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429
    CrossrefPubMedGoogle Scholar
  • 2 Van Gelder IC, Groenveld HF, Crijns HJ et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362: 1363-1373
    CrossrefPubMedGoogle Scholar
  • 3 Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation – Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356: 1789-1794
    Google Scholar
  • 4 de Denus S, Sanoski CA, Carlsson J et al. Rate vs. rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med 2005; 165: 258-262
    CrossrefPubMedGoogle Scholar
  • 5 Roy D, Talajic M, Nattel S et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667-2677
    CrossrefPubMedGoogle Scholar
  • 6 Corley SD, Epstein AE, DiMarco JP et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004; 109: 1509-1513
    CrossrefPubMedGoogle Scholar
  • 7 Dagres N, Kottkamp H, Piorkowski C et al. Influence of the duration of Holter monitoring on the detection of arrhythmia recurrences after catheter ablation of atrial fibrillation: implications for patient follow-up. Int J Cardiol 2010; 139: 305-306
    CrossrefPubMedGoogle Scholar
  • 8 Hohnloser SH, Pajitnev D, Pogue J et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 2007; 50: 2156-2161
    CrossrefPubMedGoogle Scholar
  • 9 Lafuente-Lafuente C, Mouly S, Longas-Tejero MA et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006; 166: 719-728
    CrossrefPubMedGoogle Scholar
  • 10 Freemantle N, Lafuente-Lafuente C, Mitchell S et al. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 2011; 13: 329-345
    CrossrefPubMedGoogle Scholar
  • 11 Ehrlich JR, Biliczki P, Hohnloser SH et al. Atrial-selective approaches for the treatment of atrial fibrillation. J Am Coll Cardiol 2008; 51: 787-792
    CrossrefPubMedGoogle Scholar
  • 12 Ehrlich JR, Gotte A. [Remodeling by atrial fibrillation and clinical implications for cardioversion]. Dtsch Med Wochenschr 2011; 136: 2212-2216
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 13 Ehrlich JR, Hohnloser SH. [Pharmacological cardioversion of atrial fibrillation]. Z Kardiol 2005; 94: 14-22
    CrossrefPubMedGoogle Scholar
  • 14 Klein AL, Grimm RA, Murray RD et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344: 1411-1420
    CrossrefPubMedGoogle Scholar
  • 15 Chevalier P, Durand-Dubief A, Burri H et al. Amiodarone versus placebo and classic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2003; 41: 255-262
    PubMedGoogle Scholar
  • 16 Santangeli P, Di Biase L, Pelargonio G et al. The pharmaceutical pipeline for atrial fibrillation. Ann Med 2011; 43: 13-32
    CrossrefPubMedGoogle Scholar
  • 17 Alboni P, Botto GL, Baldi N et al. Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med 2004; 351: 2384-2391
    CrossrefPubMedGoogle Scholar
  • 18 Buccelletti F, Iacomini P, Botta G et al. Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the European Medicines Agency approval: systematic review and meta-analysis. J Clin Pharmacol 2011; Epub ahead of print
    PubMedGoogle Scholar
  • 19 Roy D, Pratt CM, Torp-Pedersen C et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 2008; 117: 1518-1525
    CrossrefPubMedGoogle Scholar
  • 20 Santangeli P, Di Biase L, Burkhardt JD et al. Examining the safety of amiodarone. Expert Opin Drug Saf 2012; 11: 191-214
    CrossrefPubMedGoogle Scholar
  • 21 Hohnloser SH, Crijns HJ, van Eickels M et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668-678
    CrossrefPubMedGoogle Scholar
  • 22 Singh BN, Connolly SJ, Crijns HJ et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357: 987-999
    CrossrefPubMedGoogle Scholar
  • 23 Connolly SJ, Camm AJ, Halperin JL et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011; 365: 2268-2276
    CrossrefPubMedGoogle Scholar
  • 24 Singh BN, Connolly SJ, Crijns HJ et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357: 987-999
    CrossrefPubMedGoogle Scholar
  • 25 Kober L, Torp-Pedersen C, McMurray JJ et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358: 2678-2687
    CrossrefPubMedGoogle Scholar
  • 26 Morrow DA, Scirica BM, Karwatowska-Prokopczuk E et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007; 297: 1775-1783
    CrossrefPubMedGoogle Scholar
  • 27 Miles RH, Passman R, Murdock DK. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery baypass grafting. Am J Cardiol 2011; 108: 673-676
    CrossrefPubMedGoogle Scholar
  • 28 HARMONY:. http://www.clinicaltrials.gov/ct2/show/NCT01522651?term=HARMONY&rank=8
    PubMedGoogle Scholar
  • 29 Burashnikov A, Sicouri S, Di Diego JM et al. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol 2010; 56: 1216-1224
    CrossrefPubMedGoogle Scholar
  • 30 Scirica BM, Morrow DA, Hod H et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non-ST-segment-elevation acute coronary syndrome. Circulation 2007; 116: 1647-1652
    CrossrefPubMedGoogle Scholar